Health Digest on MSN12mon
The Jardiance Commercial Explained: Drug Uses, Side Effects, And More
The Food and Drug Administration approved Jardiance (empagliflozin) as a once-daily oral tablet to treat type 2 diabetes in ...
pharmaphorum10mon
Jardiance doesn’t cut it in post-heart attack trial
The EMPACT-MI trial found that giving Boehringer Ingelheim and Eli Lilly’s SGLT2 drug Jardiance (empagliflozin) within 14 days of an acute myocardial infarction (AMI) reduced the risk of a ...
pharmaphorum3d
FDA fast-tracks Lilly/Boehringer’s Jardiance for heart failure
Eli Lilly and Boehringer Ingelheim’s Jardiance was the first diabetes drug to lower the risk of cardiovascular disease in a clinical trial, and is now on course to be the first to have a chronic ...
Healio5h
Semaglutide may raise risk for form of optic neuropathy in adults with type 2 diabetes
Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...
Contract Pharma8h
Boehringer Ingelheim Names Brian Hilberdink as President, U.S. Human Pharma
Boehringer Ingelheim Pharmaceuticals Inc. has appointed Brian Hilberdink as President, U.S. Human Pharma.
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
BioSpace10d
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
FierceBiotech10d
Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
TCTMD29d
Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study
Compared with empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), dapagliflozin produced a similar impact on MI/stroke risk but was associated with an increased risk of heart failure (HF) ...
emjreviews.com1d
FDA fast-tracks Boehringer’s NSCLC drug review
The FDA has granted Priority Review to Boehringer Ingelheim's new drug application for its non-small cell lung cancer therapy ...
TCTMD20d
Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations
Merck), empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly), and insulin aspart (Fiasp and NovoLog; Novo Nordisk). Similarly, total spending for all 10 drugs increased from $3.5 to $27.5 billion ...